rare neurological disorders
Takeda’s zasocitinib shows high rates of skin clearance in phase 3 psoriasis studies
Globally, an estimated 64 million people have psoriasis, with about 80-90% of those having plaque psoriasis
Takeda’s new study data for oveporexton shows improvements in narcolepsy type 1
The phase 3 results show improvements in daily function, cognition and nighttime sleep
Takeda’s zasocitinib demonstrates positive results in plaque psoriasis
Around 64 million people worldwide live with psoriasis
BMS, Takeda and Astex join AI training consortium
The initiative focuses on training AI models to aid in drug discovery and development
EC approves argenx’s subcutaneous Vyvgart for rare autoimmune disease CIPD
The drug has been authorised as a monotherapy for adults with progressive or relapsing active cases
Takeda receives EC approval for Adcetris combination in Hodgkin lymphoma
The decision marks the second approval for an Adcetris-based regimen for front-line Hodgkin lymphoma
Takeda’s Adzynma approved by MHRA for rare blood clotting disorder cTTP
The enzyme replacement therapy is now the first treatment approved in the UK for this patient population
MHRA approves Bavarian Nordic’s chikungunya vaccine Vimkunya
Approximately 620,000 cases of the mosquito-borne viral disease were reported worldwide in 2024
Takeda receives CHMP recommendation for Adcetris in Hodgkin lymphoma
The EC will review the committee’s positive opinion as it makes a decision on Adcetris in this indication
Takeda receives NICE recommendation for Adcetris combination in Hodgkin lymphoma
Around 800 people in the UK are diagnosed with late-stage disease every year
Takeda/Protagonist share positive phase 3 results for rusfertide in rare blood cancer
Up to 160,000 people in the US are affected by polycythaemia vera
Takeda and EU Innovative Health Initiative launch Crohn’s disease prevention study
Approximately three million people in Europe are affected by inflammatory bowel disease